Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches
Cancers · 13.01.2025 · 17 (2) · 236
DOI: 10.3390/cancers17020236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.01.2025. Verfasst von Shabnam Eghbali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Health (USA), Conquer Cancer Young Investigator.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and, with only 15–20% of HCC patients being suitable for potentially curative treatments, the vast majority of patients with HCC ultimately require systemic therapy. For decades, the choice of effective systemic therapy for HCC remained sparse. In recent years, after the combination of atezolizumab and bevacizumab demonstrated superior overall survival over the first-line standard, sorafenib, there has been a major therapeutic paradigm shift to immunotherapy-based regimens for HCC. While representing a great leap forward for the treatment of this cancer, the reality is that less than one-third of patients achieve an objective response to immune checkpoint inhibitor-based therapy, so there remains a significant clinical need for further therapeutic optimization. In this review, we provide an overview of the current landscape of immunotherapy for unresectable HCC and delve into the tumor intrinsic and extrinsic mechanisms of resistance to established immunotherapies with a focus on novel therapeutic targets with strong translational potential. Following this, we spotlight emerging immunotherapy approaches and notable clinical trials aiming to optimize immunotherapy efficacy in HCC that include novel immune checkpoint inhibitors, tumor microenvironment modulators, targeted delivery systems, and locoregional interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.
ORCID-Profile: Shabnam Eghbali
Förderung
- NCI NIH HHS
- National Institute of Health (USA)
- Conquer Cancer Young Investigator
Zitieren
APA
Eghbali, S., & Heumann, T. R. (2025). Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches. Cancers, 17(2), 236. https://doi.org/10.3390/cancers17020236
Vancouver
Eghbali S, Heumann TR. Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches. Cancers. 2025;17(2):236. doi:10.3390/cancers17020236
BibTeX
@article{Eghbali2025,
author = {Eghbali, Shabnam and Heumann, Thatcher Ross},
title = {Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {236},
doi = {10.3390/cancers17020236}
}
EUVIMED